Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed

Serina Therapeutics, Inc.

Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.
FDA IND cleared for SER-252 (advanced Parkinson's); first patient dosed in Phase 1b trial in February 2026.
Private placement of up to $30M closed; $16M received as of March 23, 2026; Greg Bailey appointed Co-Chairman.
ATM program raised $12.9M from 3.5M shares at avg $3.72; additional $10M raised in 2026.
Cash and cash equivalents $3.1M as of December 31, 2025.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Serina Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $19.4 million, EPS $(1.91) per basic and diluted share.

Period: the year ended December 31, 2025
Net income: $19.4 million
EPS: $(1.91) per basic and diluted share
Result: reported results

Exact text from the filing

The net loss attributable to Serina common stockholders for the year ended December 31, 2025 was $19.4 million, or $(1.91) per basic and diluted share

View on SEC.gov

41 earnings releases filed in the last 30 days. Browse all earnings releases →

Serina Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001708599-26-000018

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.